Nektar Therapeutics
NKTR
39.73
-0.53
-1.32%
Nektar Therapeutics
US · NKTR
#3017 by market cap
Listed 1970
39.73
-0.53
-1.32%
Live - 5344 symbols - heartbeat 549s ago
· 2026-10-08 10:00
Pre-market
39.92
-0.84%
After-hours
40.00
-0.65%
Overnight
40.20
-0.15%
- Market cap
- 1.36B
- P/E (TTM)i
- -6.49
- P/Bi
- 1.50
- EPSi
- -9.73
- Div yieldi
- 0.00%
- 52W posi
- 8%
Reader sentiment
Are you bullish or bearish on NKTR?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 9 analysts
Buy
Avg price target
155.57 +291.6%
Price target rangecurrent 39.73
Low80.00
Avg155.57
High192.00
Buy 89%
Hold 11%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-05 | Citi | -- | BUY | 151.00 |
| 2026-10-02 | H.C. Wainwright | -- | BUY | 185.00 |
| 2026-10-01 | William Blair | -- | BUY | -- |
| 2026-10-01 | Jefferies | -- | BUY | 150.00 |
| 2026-10-01 | H.C. Wainwright | -- | BUY | 185.00 |
| 2026-09-29 | BTIG | -- | BUY | 178.00 |
| 2026-09-28 | CCORF | -- | BUY | 153.00 |
| 2026-09-25 | BTIG | -- | BUY | 178.00 |
| 2026-09-17 | BTIG | -- | BUY | 178.00 |
| 2026-09-16 | BTIG | -- | BUY | 178.00 |
| 2026-08-20 | Piper Sandler | -- | BUY | 192.00 |
| 2026-08-17 | CCORF | -- | BUY | 153.00 |
| 2026-08-17 | H.C. Wainwright | -- | BUY | 185.00 |
| 2026-08-14 | William Blair | -- | BUY | -- |
| 2026-08-14 | Piper Sandler | -- | BUY | 192.00 |
| 2026-08-14 | Wedbush | -- | HOLD | 80.00 |
| 2026-08-14 | Citi | -- | BUY | 151.00 |
| 2026-08-13 | TD Cowen | -- | BUY | -- |
| 2026-08-13 | BTIG | -- | BUY | 178.00 |
| 2026-08-05 | CCORF | -- | BUY | 153.00 |
| 2026-07-22 | CCORF | -- | BUY | 153.00 |
| 2026-07-21 | Citi | -- | BUY | 151.00 |
| 2026-07-13 | BTIG | -- | BUY | 178.00 |
| 2026-07-01 | H.C. Wainwright | -- | BUY | 185.00 |
| 2026-05-13 | Citi | -- | BUY | 151.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: William Blair moved from Hold to Buy on 2026-02-10.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-02-10 | William Blair | HOLD → BUY | -- |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-13 | After close | ±5.18% | -3.82% (in line) |
| 2026/Q1 | 2026-05-07 | After close | ±8.46% | -1.78% (in line) |
| 2025/Q4 | 2026-03-12 | After close | ±7.90% | +4.11% (in line) |
| 2025/Q3 | 2025-11-06 | After close | ±15.46% | +1.54% (in line) |
| 2025/Q2 | 2025-08-07 | After close | ±14.55% | +6.02% (in line) |
| 2025/Q1 | 2025-05-08 | After close | ±40.39% | -4.88% (in line) |
| 2024/Q4 | 2025-03-12 | After close | ±39.75% | -0.56% (in line) |
| 2024/Q3 | 2024-11-07 | After close | ±36.86% | +2.19% (in line) |
| 2024/Q2 | 2024-08-08 | After close | ±58.76% | -8.26% (in line) |
| 2024/Q1 | 2024-05-09 | After close | ±30.06% | +10.00% (in line) |
| 2023/Q4 | 2024-03-04 | After close | ±47.78% | -1.77% (in line) |
| 2023/Q3 | 2023-11-07 | After close | ±96.72% | -8.76% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 10:00:07 · For reference only, not investment advice and not tailored to your situation.